Ken Cohen is an independent adviser to entrepreneurs, companies and investors, primarily in the life sciences, and an experienced corporate director and board chairman. Ken was previously Co-founder, President and CEO of Somaxon Pharmaceuticals, a specialty pharmaceutical company. He was President and CEO of Synbiotics Corporation, a veterinary diagnostics company, and was Executive Vice
President and COO for Canji, a gene-therapy company, until its acquisition by Schering-Plough in 1996. He served as Vice President of Business Affairs at Argus Pharmaceuticals and VP of Marketing & Business Development for LifeCell Corporation.
Ken held numerous positions during 10 years at Eli Lilly, including Director of Business Planning for Medical Instrument Systems, which became Guidant, and managed the launch of Prozac®, one of the most successful drugs of all time.
Ken received his A.B. degree from Dartmouth College and an M.B.A. from the Wharton School. In 1999, in recognition of his contributions to French-American business, the President of the Republic of France named Ken a Chevalier of the National Order of Merit.
Mr. Cohen is presently a Director of MabVax Therapeutics (OTC:MBVX), Euclid Vision Systems, and a member of the Board of Trustees of the San Diego Humane Society.